Key result
Review summarizes trial evidence for GP IIb-IIIa inhibitors in acute ischemic syndromes and percutaneous revascularization.
Why the study?
Do inhibitors of platelet GP IIb-IIIa improve outcomes in patients with acute coronary syndromes or undergoing percutaneous coronary revascularization?
Do inhibitors of platelet GP IIb-IIIa improve outcomes in patients with acute coronary syndromes or undergoing percutaneous coronary revascularization?
This review summarizes the clinical evaluation of GP IIb-IIIa inhibitors as therapeutics for acute ischemic syndromes and adjuvants for percutaneous revascularization.
Answers are grounded in this paper and cite their sources.
Synthesizes trial evidence on GP IIb-IIIa inhibitors in ACS and PCI; leaves open their role amid evolving antithrombotic strategies.
Platelet activation is a critical mechanism in acute coronary artery syndromes and ischemic complications of percutaneous coronary revascularization. Thrombin and platelet inhibition are the current mainstays of therapy for these problems. Inhibitors of platelet GP IIb-IIIa, the final common pathway of platelet aggregation, have recently undergone clinical evaluation as therapeutics for acute ischemic syndromes, and as adjuvants for percutaneous revascularization. The results of these prospective, controlled trials, and current evaluations of GP IIb-IIIa inhibitors are summarized in this review.
No takes yet. Share an insight, caveat, or question.
Aaron D. Kugelmass (1997) conducted a review in Acute coronary syndromes and ischemic complications of percutaneous coronary revascularization. Inhibitors of platelet GP IIb-IIIa was evaluated. This review summarizes the results of prospective, controlled trials evaluating platelet GP IIb-IIIa inhibitors as therapeutics for acute ischemic syndromes and adjuvants for percutaneous revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: